MGTX
NASDAQ · Biotechnology
Meiragtx Holdings Plc
$9.49
-0.22 (-2.22%)
Financial Highlights (FY 2026)
Revenue
98.29M
Net Income
-137,926,162
Gross Margin
94.0%
Profit Margin
-140.3%
Rev Growth
+72.3%
D/E Ratio
1.08
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 94.0% | 94.1% | 65.8% | 65.8% |
| Operating Margin | -130.2% | -117.2% | -9.9% | -11.8% |
| Profit Margin | -140.3% | -133.3% | -10.4% | -12.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 98.29M | 57.06M | 298.22M | 353.14M |
| Gross Profit | 92.45M | 53.66M | 196.30M | 232.45M |
| Operating Income | -127,978,634 | -66,860,608 | -29,566,882 | -41,721,150 |
| Net Income | -137,926,162 | -72,057,552 | -30,982,952 | -42,442,765 |
| Gross Margin | 94.0% | 94.1% | 65.8% | 65.8% |
| Operating Margin | -130.2% | -117.2% | -9.9% | -11.8% |
| Profit Margin | -140.3% | -133.3% | -10.4% | -12.0% |
| Rev Growth | +72.3% | +72.3% | -0.7% | -1.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 232.21M | 232.21M | 274.26M | 257.56M |
| Total Equity | 215.11M | 215.11M | 356.05M | 341.85M |
| D/E Ratio | 1.08 | 1.08 | 0.77 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -127,619,827 | -70,377,219 | -39,492,333 | -49,405,433 |
| Free Cash Flow | — | — | -35,501,473 | -31,424,329 |